ArticleTheranostics2019
Low Levels of Sox2 are required for Melanoma Tumor-Repopulating Cell Dormancy.
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Regulating the dormancy of cancer stem cells: a novel approach to preventing cancer relapse.Cell death & disease · 2026Review
- The enigmatic role of tumor dormancy cells in gynecologic cancers.Frontiers in immunology · 2026Review
- Dormancy of cutaneous melanoma.Cancer cell international · 2024Review
- Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy.Frontiers in immunology · 2024Review
- Cellular Dormancy in Cancer: Mechanisms and Potential Targeting Strategies.Cancer research and treatment · 2023Review
- Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution.Cancer metastasis reviews · 2023Review
- Dexamethasone and OLT1177 Cooperate in the Reduction of Melanoma Growth by Inhibiting STAT3 Functions.Cells · 2023Article
- Radiated tumor cell-derived microparticles effectively kill stem-like tumor cells by increasing reactive oxygen species.Frontiers in bioengineering and biotechnology · 2023Article
- Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.Experientia supplementum (2012) · 2022Article
- Targeting Indoleamine 2,3-Dioxygenase 1: Fighting CancersFrontiers in immunology · 2021Review
- Autophagy and Cancer Dormancy.Frontiers in oncology · 2021Review
- Carcinoma-Associated Fibroblasts Promote Growth of Sox2-Expressing Breast Cancer Cells.Cancers · 2020Article
- ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL.Nature communications · 2020Article
- The current paradigm and challenges ahead for the dormancy of disseminated tumor cells.Nature cancer · 2020Review
- Two-dimensional nanomaterials beyond graphene for antibacterial applications: current progress and future perspectives.Theranostics · 2020Review
- Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening.Frontiers in immunology · 2020Review
- Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment.Frontiers in oncology · 2020Review
- Graphene and other 2D materials: a multidisciplinary analysis to uncover the hidden potential as cancer theranostics.Theranostics · 2020Review
- Review
- PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity.Journal for immunotherapy of cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumorigenic cells, when facing a hostile environment, may enter a dormant state, leading to long-term tumor survival, relapse, and metastasis. To date, the molecular mechanism of tumor cell dormancy remains poorly understood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.